翰森製藥(03692.HK):創新藥艾米替諾福韋片被納入國家醫保目錄
格隆匯12月3日丨翰森製藥(03692.HK)宣佈,公司附屬江蘇豪森藥業集團有限公司自主研發的創新藥”艾米替諾福韋片“(商品名:恆沐®)被納入中國國家醫療保障局發佈的新版國家醫保目錄(”國家醫保目錄“)。
該產品於2021年6月獲得中華人民共和國國家藥品監督管理局頒發藥品註冊批件,系適用於治療成人患者慢性乙型肝炎的抗感染藥物。
公吿稱,該產品被納入國家醫保目錄將有助於集團進一步提高該產品在患者中的可負擔性和可及性。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.